Evidence map›Paper›PMID 34299424›Full record

ArticleMolecules (Basel, Switzerland)2021

The Regulatory Effects of Licochalcone A on the Intestinal Epithelium and Gut Microbiota in Murine Colitis.

Juan Zhang, Li Cao, Yu Sun, De-Gang Qing, Xiao-Qin Xu, Jun-Chi Wang, Jian-Yong Si, Ning Li

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Chalcones and Gastrointestinal Cancers: Experimental Evidence.International journal of molecular sciences · 2023
    Review
  8. Article
  9. Frontiers in microbiology · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Juan ZhangInstitute of Medicinal Plant Development, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100193, China.ORCID 0000-0002-3216-1162
Li CaoInstitute of Medicinal Plant Development, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100193, China.
Yu SunXinjiang Institute of Chinese Materia Medica and Ethnodrug, Ürümqi 830002, China.
De-Gang QingXinjiang Institute of Chinese Materia Medica and Ethnodrug, Ürümqi 830002, China.
Xiao-Qin XuXinjiang Institute of Chinese Materia Medica and Ethnodrug, Ürümqi 830002, China.
Jun-Chi WangInstitute of Medicinal Plant Development, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100193, China.
Jian-Yong SiInstitute of Medicinal Plant Development, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100193, China.
Ning LiSchool of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang 110016, China.
Chinese Academy of Medical Sciences & Peking Union Medical College · CNXinjiang Institute of Materia Medica · CNShenyang Pharmaceutical University · CN

Funding

National Natural Science Foundation of China 81660654Science and Technology Assistance Project of Xinjiang 2018E02071Science and Technology Talents Project of Urumqi 2021-2022Tianshan Talents Program 2021-2023
6 · The paper itself

Abstract

The gut epithelium is a mechanical barrier that protects the host from the luminal microenvironment and interacts with the gut microflora, which influences the development and progression of ulcerative colitis (UC). Licochalcone A (LA) exerts anti-inflammatory effects against UC; however, whether it also regulates both the gut barrier and microbiota during colitis is unknown. The current study was conducted to reveal the regulatory effects of LA on the intestinal epithelium and gut microflora in C57BL/6 mice subjected to dextran sodium sulfate (DSS). Sulfasalazine (SASP) was used as the positive control. Results of clinical symptoms evaluation, hematoxylin, and eosin (H&E) staining, and enzyme-linked immunosorbent (ELISA) assays showed that LA significantly inhibited DSS-induced weight loss, disease activity index (DAI) increase, histological damage, and gut inflammation. Additionally, terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) and immunohistochemical (IHC) analysis showed that LA maintained the integrity of the intestinal barrier by suppressing cell apoptosis and preserving the expression of tight junction (TJ) proteins. Notably, the optimal dose of LA for gut barrier preservation was low, while that for anti-inflammatory effects was high, indicating that LA might preserve gut barrier integrity via direct effects on the epithelial cells (ECs) and TJ proteins. Furthermore, 16S rRNA analysis suggested that the regulatory effect of LA on the gut microbiota differed distinctly according to dose. Correlation analysis indicated that a low dose of LA significantly modulated the intestinal barrier-associated bacteria as compared with a moderate or high dose of LA. Western blot (WB) analysis indicated that LA exhibited anti-UC activity partly by blocking the mitogen-activated protein kinase (MAPK) pathway. Our results further elucidate the pharmacological activity of LA against UC and will provide valuable information for future studies regarding on the regulatory effects of LA on enteric diseases.

Indexed as

AnimalsChalconesColitisColitis, UlcerativeColonDextran SulfateDisease Models, AnimalGastrointestinal MicrobiomeIntestinal MucosaMaleMiceMice, Inbred C57BLSulfasalazineTight Junction ProteinsChalconesDextran Sulfatelicochalcone ASulfasalazineTight Junction Proteinsgut barrierLicochalcone AMAPKmicrobiotaulcerative colitis

Identifiers

PMID34299424
PMCPMC8304238
OpenAlexW3180749464

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.